Abstract We evaluate the long-term prognosis and prognostic factors in patients treated with transarterial infusion chemotherapy using cisplatin-lipiodol (CDDP/LPD) suspension with or without embolization for unresectable hepatocellular carcinoma (HCC). Study subjects were 107 patients with HCC treated with repeated transarterial infusion chemotherapy alone using CDDP/LPD (adjusted as CDDP 10mg/LPD 1ml). The median number of transarterial infusion procedures was two (range, one to nine), the mean dose of CDDP per transarterial infusion chemotherapy session was 30 mg (range, 5.0-67.5 mg), and the median total dose of transarterial infusion chemotherapy per patient was 60 mg (range, 10-390 mg). Survival rates were 86% at 1 year, 40% at 3 years, 20% at 5 years, and 16% at 7 years. For patients with [90% LPD accumulation after the first transarterial infusion chemotherapy, rates were 98% at 1 year, 60% at 3 years, and 22% at 5 years. Multivariate analysis identified [90% LPD accumulation after the first transarterial infusion chemotherapy (p = 0.001), absence of portal vein tumor thrombosis (PVTT; p \ 0.001), and Child-Pugh class A (p = 0.012) as independent determinants of survival. Anaphylactic shock was observed in two patients, at the fifth transarterial infusion chemotherapy session in one and the ninth in the other. In conclusion, transarterial infusion chemotherapy with CDDP/LPD appears to be a useful treatment option for patients with unresectable HCC without PVTT and in Child-Pugh class A. LPD accumulation after the first transarterial infusion chemotherapy is an important prognostic factor. Careful consideration should be given to the possibility of anaphylactic shock upon repeat infusion with CDDP/LPD.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide [1] [2] [3] [4] . Recent advances in imaging and treatment modalities have resulted in a number of improvements in the prognosis of patients with HCC. Patients with small HCCs, for example, are commonly treated by surgical resection and locoregional therapy such as percutaneous ethanol injection (PEI), microwave coagulation therapy, laser ablation, and radiofrequency (RF) ablation, and these treatments are often associated with a satisfactory long-term prognosis [5] [6] [7] [8] [9] . However, these locoregional therapies are not suitable in all patients, mainly due to the presence of a large tumor, multiple HCC tumors, or a serious underlying chronic liver disorder.
Since the development of transcatheter arterial embolization (TAE) for HCC [10] [11] [12] , intra-arterial treatments have been widely used for patients with unresectable HCC.
Among these, transcatheter arterial chemoembolization (TACE) using anticancer drugs mixed with lipiodol (LPD; Lipiodol Ultrafluide; Laboratoire Guerbet, Aulnay-SousBois, France), which remains selectively in tumor tissue for extended periods of time, has now become one of the most effective treatment modalities for patients with unresectable HCC [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . Randomized controlled trials recently confirmed the survival benefits of TACE in such patients [28, 29] .
Various anticancer drugs have been used as TACE agents in the treatment of HCC, including doxorubicin hydrochloride (ADM) [13] [14] [15] [16] , epirubicin hydrochloride [17] , mitomycin C (MMC) [13, 16] , zinostatin stimalamer (SMANCS) [27] , and cisplatin (cis-diaminedichloroplatinum; CDDP) [30] [31] [32] [33] . However, the most effective of these anticancer drugs and protocols against HCC has yet to be identified. In particular, little or no information is available on the effects of TACE-CDDP/LPD on prognosis or on the factor(s) predictive of a response.
We conducted a retrospective study to determine the long-term prognosis of patients who received transarterial infusion chemotherapy with CDDP/LPD for unresectable HCC and identified the factor(s) predictive of long-term prognosis.
Materials and Methods

Patients
From June 2000 to December 2007, 526 patients with naïve HCC were admitted to our hospital. Of these, 323 patients were treated with transarterial infusion chemotherapy, 68 with surgical resection, 5 with living-donor liver transplantation (LDLT), 54 with RF ablation, 13 with PEI, 4 with RF ablation and PEI, 32 with hepatic arterial infusion chemotherapy, 3 with systemic chemotherapy, and 24 with conservative therapy. Of the 323 patients treated with transarterial infusion chemotherapy, 91 were later treated with surgical resection, 41 with RF ablation, 35 with transarterial infusion chemotherapy combined with PEI, 7 with LDLT, 7 with radiotherapy, 32 with hepatic arterial infusion chemotherapy, and 3 with a combination of systemic chemotherapy, leaving 107 patients treated with transarterial infusion chemotherapy alone for enrollment in this retrospective cohort study. The study group consisted of 75 men and 32 women ranging in age from 42 to 92 years (median, 73 years). Tests were positive for hepatitis C virus in 82 patients (78.8%) and for hepatitis B virus in 7 patients (6.7%). Seventy-five patients were classified as having Child-Pugh class A (72.1%) disease and 29 as Child class B disease (27.9%). Median total bilirubin level was 1.0 mg/dl, and median serum albumin was 3.6 g/dl. Tumor staging was defined based on the tumor node metastasis staging system of the Liver Cancer Study Group of Japan (LCSGJ): stage I (fulfilling three intrahepatic conditions: solitary, \2 cm, no vessel invasion; n = 9 [9%]), stage II (two of the three intrahepatic conditions; n = 41 [38%]), stage III (one of the three intrahepatic conditions; n = 53 [50%]), stage IVa (none of the three intrahepatic conditions, with no distant metastases or any intrahepatic conditions with lymph node metastases), and stage IVb (any intrahepatic condition with distant metastases; stage IV, n = 4 [3%]) [34] . The median value of the maximum diameter of the main tumor was 30 mm (range, 6-130 mm). Forty-three (40%) patients had a solitary tumor, 35 (33%) had two or three tumors, and 29 (27%) had four or more tumors. The clinical characteristics of the study group are summarized in Table 1 . The study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the ethics committee of our hospital, and written informed consent was obtained from all participating patients.
Preparation of Chemotherapeutic Agents
LPD was mixed at 1 ml per 10 mg CDDP powder. Because CDDP powder was not available for clinical use in Japan from June 2000 to December 2004, we prepared CDDP powder from a commercially available CDDP solution (Randa; Nippon Kayaku, Tokyo) as described in our previous study [35] . After it became available, from December 2004 to December 2007, we mixed CDDP powder with LPD (IA-call; Nippon Kayaku). The particle size of CDDP powder is 28.5 lm.
Imaging and Confirmation of Diagnosis
Pretreatment imaging studies included abdominal ultrasonography (US), contrast-enhanced dynamic CT, dynamic magnetic resonance (MR) imaging, digital subtraction angiography (DSA), angiography combined with CT during arterial portography (CTAP), and hepatic arteriography (CTHA). All tumors were diagnosed by distinctive findings on US, dynamic CT and/or dynamic MR imaging, DSA, CTAP, and CTHA. Diagnosis was confirmed by early enhancement in the arterial phase and hypoattenuation in the portal venous or equilibrium phase on contrastenhanced dynamic CT or dynamic MR images, or by hypoattenuation on CTAP and hyperattenuation on CTHA.
In addition, changes in serum tumor markers (a-fetoprotein [AFP] or des-c-carboxy prothrombin) were used to support the imaging-based diagnosis.
Transarterial Infusion Chemotherapy with or Without Embolization
Transarterial infusion chemotherapy was performed through the femoral artery under local anesthesia using the technique of Seldinger. An angiographic catheter was inserted into the hepatic feeding artery of the segment or subsegments containing the target tumor under CT scan during hepatic arteriography and arterial portography. We used a CDDP/LPD suspension as an anticancer drug. The tumor vessels were evaluated by CTHA scans during hepatic arteriography. Dosage was based on tumor size, and injection was discontinued based on the full accumulation of iodized oil in the tumor vessels and the degree of visualization of the portal vein during injection on fluoroscopy. The accumulation of iodized oil in the tumor was evaluated by CTHA scan; if accumulation in the tumor was poor, other vessels were tested, and when a vessel was identified as a feeding vessel, CDDP/LPD was added to the infusion. CDDP/LPD was not injected into the right hepatic artery, left hepatic artery, or proper hepatic artery. A gelatin sponge was used for embolization (Gelpart; Nippon Kayaku, Tokyo), cut into 1-or 2-mm cubes, depending on the vascular diameter. The gelatin sponge was used after arterial infusion chemotherapy in patients who had a membrane-covered lesion and a segmental lesion in the periphery. Most patients were treated by arterial infusion chemotherapy in principle, but a gelatin sponge was not used in all patients, particularly those with chronic liver failure. A gelatin sponge was not used on the right hepatic artery, left hepatic artery, or proper hepatic artery. The angiographic endpoint of gelatin sponge embolization was very mild embolization. Extrahepatic collateral arteries which supplied tumors were also embolized.
The fluid replacement volume was 3000 ml/day on the day of treatment and 1000 ml/day for the next 2 days.
Criteria for Evaluation of the Therapeutic Effect of Transarterial Infusion Chemotherapy with or Without Embolization
The efficacy of transarterial infusion chemotherapy was evaluated by CT at 3 months after treatment, as follows: when LPD was seen in [90% of the tumor, efficacy was considered grade I; in 50% to 90% of the tumor, grade II; and in \50% of the tumor, grade III [35] . Grading for LPD retention was based on quantitative measurement of tumor diameter in all tumors, based on the assumption that the tumor portion with retained LPD was necrotic tissue. The percentage of LPD accumulation in the target tumor was graded by two radiologists blinded to clinical status. Discrepancies between the two observers were resolved by adopting the lowest grade of assessment.
Follow-Up Protocol
Concentrations of serum tumor markers, including AFP and des-c-carboxy prothrombin, were measured once a month after transarterial infusion chemotherapy; follow-up US was performed every 3 months; and CT or MR imaging was performed every 6 months. Patients showing an increase in tumor markers, diminution of LPD accumulation, or new nodules remote from the treated nodules were readmitted for an additional round of transarterial infusion chemotherapy using the same procedure. On follow-up, patients treated with transarterial infusion chemotherapy who did not show complete uptake of LPD (i.e., those classified as grade I), but did show the presence of a viable tumor, namely, by arterial phase enhancement on CT/MR, were retreated with transarterial infusion chemotherapy within 3-6 months of the first treatment. Patients with tumor progression, appearance of PVTT, and liver failure were excluded from TACE.
Complications
Major complications were defined in accordance with the definitions established by the Society of Interventional Radiology as hemorrhage requiring transfusion, liver abscess requiring percutaneous drainage, bile duct injury requiring biliary drainage, pleural effusion requiring thoracocentesis, hepatic failure, and death [36] . In all patients, the following laboratory tests were conducted before treatment and 1, 3, and 7 days after and 1 month after treatment: serum transaminases, bilirubin, alkaline phosphatase, albumin, creatinine, and complete blood cell count. Adverse reactions were assessed using the National Cancer Institute Common Toxicity Criteria (NCI-CTC; version 3.0) [37] .
Statistical Analysis
Data were collected and calculated at the end of the study and statistically analyzed on April 1, 2008. Cumulative survival rate was calculated from the initial date of transarterial infusion chemotherapy therapy and assessed by the Kaplan-Meier life-table method, with differences evaluated by the log rank test. Univariate analysis of predictors of survival was assessed by the Kaplan-Meier lifetable method, and differences were evaluated by the log rank test. Multivariate analysis of predictors of survival was assessed by the Cox proportional hazards model. Statistical significance was defined as a p value \0.05. We also calculated hazard ratios and 95% confidence intervals (95% CI). All p values \0.05 in two-tailed tests were considered significant. Variables that achieved statistical (p \ 0.05) or marginal significance (p \0.10) in univariate analysis were entered into a multiple Cox proportional hazards model to identify significant independent factors. Parameters used for the prediction of survival were LPD accumulation, tumor number, PVTT (present or absence), Child-Pugh class, AFP, age, gender, etiology, TAE (with or without embolization), and tumor size. All analyses were performed with SPSS software (version 16; SPSS, Chicago, IL).
Results
Therapeutic Effects of Transarterial Infusion Chemotherapy-CDDP/LPD
The median number of transarterial infusion chemotherapy procedures per patient was two (range, one to nine). The mean dose of CDDP per single session of transarterial infusion chemotherapy was 30 mg (range, 5.0-67.5 mg), and the median total dose of CDDP per patient was 60 mg (range, 10-390 mg). LPD accumulation was evaluated after the first transarterial infusion chemotherapy: grade I was recorded in 58 patients (55%), grade II in 36 (33%), and grade III in 13 (12%) ( Table 2 ).
Survival Rates
Cumulative survival curves of patients treated with TACE using CDDP/LPD suspension for unresectable HCC. Survival rates were 86% at 1 year, 40% at 3 years, 20% at 5 years, and 16% at 7 years. No significant difference in overall survival was seen between patients with and those without embolization (p = 0.20) (Fig. 1) . Survival rate in patients assessed as grade I was 98% at 1 year, 60% at 3 years, and 22% at 5 years. Respective rates, in contrast, were 68%, 52%, and 22% in those assessed as grade II and 48%, 20%, and 0% in those assessed as grade III (Fig. 2) . The probability of survival correlated with the extent of LPD accumulation in grades I and III (p \ 0.05). Representative examples of patients with grades I and II are shown in Fig. 3 .
We then investigated the relationship between survival after the initiation of transarterial infusion chemotherapy and various clinicopathological variables by univariate analysis. Results showed that survival correlated significantly with grade I (p = 0.001), and AFP \ 200 ng/ml (p = 0.013) ( Table 3) . grade I, absence of PVTT, ChildPugh class A, number of tumors = 1, and AFP \ 200 ng/ ml were then entered into the multiple Cox proportional hazard model, which identified grade I (p = 0.001), absence of PVTT (p \ 0.001) and Child-Pugh class A Survival rate (%) Fig. 1 Cumulative survival curves of patients treated with TACE using CDDP/LPD suspension for unresectable HCC. Survival rates were 96% at 1 year, 36% at 3 years, 24% at 5 years, and 24% at 7 years in with embolization groups and 72% at 1 year, 40% at 3 years, 16% at 5 years in without embolization groups. No significant difference in overall survival was seen between patients with and without embolization (p = 0.20)
(p = 0.012) as significant and independent determinants of survival.
Adverse Reactions and Complications
The total number of transarterial infusion chemotherapy procedures was 274. The most common adverse reactions were fever, nausea, and loss of appetite. Among patients with various NCI-CTC grade 2 adverse reactions, nausea and/or vomiting was the most common (96 patients; 35%), followed by grade 1 fever (71 patients; 26%), grade 3 thrombocytopenia (60; 22%), grade 2 abdominal pain (26; 9%), grade 2 liver dysfunction (26; 9%), grade 3 liver dysfunction (8; 3%), grade 3 renal dysfunction (2; 0.7%), grade 4 liver dysfunction (2; 0.7%), and anaphylactic shock (2; 0.7%). No intrahepatic biloma or liver abscess formation was seen. One patient received nine courses of transarterial infusion chemotherapy, with a total dose of CDDP of 310 mg. On injection of 15 mg/1.5 ml of CDDP/LPD suspension into the catheter on the ninth transarterial infusion chemotherapy, the patient experienced a decrease in systolic blood pressure from 110 to 78 mmHg and shortness of breath. He was successfully treated with oxygen and intravenous epinephrine and corticosteroid and was moved to the intensive care unit; he improved after 24 h and was transferred back to the general ward. Another patient received five courses of transarterial infusion chemotherapy, with a total dose of CDDP of 95 mg. Injection of 20 mg/2 ml of CDDP/LPD suspension into the catheter on the fifth transarterial infusion chemotherapy resulted in anaphylactic shock, but this patient also subsequently improved within 24 h.
Causes of Death
Forty-five of the 107 patients died during the study period. Causes of death were HCC-related (rupture of HCC) in 23 (51%), hepatic failure in 8 (18%), rupture of esophageal varices in 3 (7%), and other diseases in 11 (24%). No immediate or procedure-related death was seen within 30 days of infusion.
Discussion
The prognosis of patients with small HCC has improved markedly in recent years following the introduction of locoregional therapies. However, these therapies are not indicated in many patients due to large tumor size, multiple tumors, and poor underlying liver status. TACE has been widely used for these patients. Although various anticancer agents have been used as TACE agents for unresectable HCC, including ADM, epirubicin hydrochloride, MMC, SMANCS, and CDDP, the most effective anticancer drug for HCC remains to be defined. In vitro testing has indicated the efficacy of CDDP as suitable for TACE [38] , but only a few reports have described the determinants of survival after initiation of TACE with CDDP/LPD suspension [39] . The purpose of the present study was to investigate the long-term prognosis of patients undergoing transarterial infusion chemotherapy with CDDP/LPD suspension for unresectable HCC and factors predictive of prognosis. Overall survival rates in the 107 enrolled patients were 86% at 1 year, 40% at 3 years, 20% at 5 years, and 16% at 7 years. Ono et al. [39] reported survival rates of patients with unresectable HCC of 30% at 3 years with CDDP/LPD compared with 14% at 3 years with ADM. In other studies, survival rates at 3 years for unresectable HCC were 56% with ADM [40] and 32% with epirubicin hydrochloride [41] . Thus, the survival rate at 3 years achieved in the present study is very similar to those reported for ADM and epirubicin hydrochloride. The determinants of survival in the present study were grade I ([90% LPD accumulation in the first transarterial infusion chemotherapy), Child-Pugh grade A, and absence of PVTT; indeed, for patients with unresectable HCC free of PVTT who are rated as ChildPugh grade A, a comparatively excellent long-term prognosis is expected for those who show [90% LPD accumulation after the first transarterial infusion chemotherapy.
CDDP is a potent anticancer drug against HCC in vitro. Using the 3-(4,5-dimethyithiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MMT) assay, Furukawa et al. [38] [35] reported that the survival rate was significantly better for the CDDP/LPD group than for the ADM/LPD group.
Comparison of the effects of and long-term prognosis for these anticancer drugs when used as TACE agents in randomized control trial studies is required. LPD accumulation [90% after the first transarterial infusion chemotherapy was an independent determinant of survival. The proportion of patients who achieved this after the first transarterial infusion chemotherapy (55%) in the present study was higher than the 15% reported in our previous study [35] . This difference might be due to our present use of angiography combined with CT during arterial portography and hepatic arteriography, which provides better evaluation of drug accumulation in real time and, hence, allows the addition of an additional dose or drug when needed. In addition, CDDP/LPD was not injected into the right hepatic artery, left hepatic artery, or proper hepatic artery.
It seems that grading LPD uptake serves instead to represent a method to assess underlying tumor biology. Favorable tumor biology manifests with tumor necrosis and a high degree of LPD uptake, such as the case shown in Fig. 3 , while unfavorable tumor biology results in lesser degrees of tumor necrosis and secondarily lower LPD uptake. It is doubtless that the effects of TACE are affected mainly by embolization with LPD and gelatin sponge. However, no significant difference in overall survival was seen between patients with and those without embolization in our study.
Ikeda et al. also reported that although transcatheter arterial infusion chemotherapy had a stronger antitumor effect than transarterial infusion chemotherapy, it did not significantly improve survival [42] . In contrast, Yamamoto et al. reported that complete embolization after injection of cisplatin-lipiodol suspension resulted in higher survival than incomplete embolization [32] . We consider that gelatin sponge embolization was locally effective in the tumor, but because survival rates were also related to liver function, gelatin sponge embolization was not a significant prognostic factor in this study.
Although we used a CDDP/LPD suspension in the present study, Takaki et al. recently reported that LPD retention was better with the emulsion than with the suspension [43] . Evaluation of the best mixing method for CDDP and LPD requires long-term investigation.
Analysis of adverse reactions and complications with transarterial infusion chemotherapy-CDDP/LPD showed minimal renal or liver dysfunction. This favorable finding may be due to selective infusion of the drug under CTAP and CTHA: because the injected area can be viewed directly under CTHA, the amount of injected drug that can cause damage to noncancer tissue is minimal [44] , and the mean dose of CDDP per single session of transarterial infusion chemotherapy was a relatively low 30 mg. Nevertheless, anaphylactic shock was observed in two (0.7%) patients. A recent review reported five patients with gynecological malignancies who experienced anaphylaxis to CDDP after receiving previously uncomplicated courses of this agent, with the hypersensitivity reaction following a median of seven courses [45, 46] . In our study, two patients experienced hypersensitivity, at the fifth and ninth courses, respectively, suggesting the need for caution when administering platinum agents to patients previously treated with the agent. Monitoring during CDDP/LPD injection is therefore warranted, and injection should be stopped at the first sign of symptoms.
In conclusion, transarterial infusion chemotherapy with CDDP/LPD appears to be a useful treatment option for patients with unresectable HCC without PVTT and in Child-Pugh class A. LPD accumulation after the first transarterial infusion chemotherapy is an important prognostic factor. Careful consideration should be given to the possibility of anaphylactic shock upon repeat infusion with CDDP/LPD.
